4-chloro-N-methoxy-N,3-dimethylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-N-methoxy-N,3-dimethylbenzamide
• 英文别名: 4-chloro-N-methoxy-3,N-dimethylbenzamide
• 化学式: C₁₀H₁₂ClNO₂
• 分子量: 213.664
• InChiKey: BMAQQBYNHFYZEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-N-methoxy-N,3-dimethylbenzamide 在 哌啶 、 溶剂黄146 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-benzyl-1-(4-chloro-3-methylphenyl)prop-2-en-1-one
  参考文献：
  名称：

  Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands

  摘要：

  In line of a scaffold hopping strategy of pyrazole structures, especially known as potent CB2 receptor antagonists, we exploited an original and convergent synthesis of a new class of C4-benzyl pyrazolines and derivatives from readily available hydrazones and enones (two or three steps). Making use of a mixture of resin supported reagents strategy an efficient domino process allowed the easy construction of various dihydropyrazoles in 63-83% yields. The obtained family of pyrazolines featured significant hCB(2)/hCB(1) selectivity in favor of hCB(2) receptors while more than 1000-3000 nM affinity was only measured for hCB(1) receptors. This is closely related to pyrazole SR144528 inverse agonist/antagonist, although a partial agonist behavior in the [S-35]-GTP gamma S binding assay was mainly measured in our case pointing out a functional switch in action. Furthermore, this hCB(2) selectivity is unique within the pyrazoline CB ligands although the affinity ranging from 251 to 689 nM remains to be improved which give, however, an opportunity for further structure activity relationship. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.10.031
• 作为产物：
  描述：

  4-氯-3-甲基苯甲酸 、 二甲羟胺盐酸盐 在 N,N'-羰基二咪唑 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以96%的产率得到4-chloro-N-methoxy-N,3-dimethylbenzamide
  参考文献：
  名称：

  Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands

  摘要：

  In line of a scaffold hopping strategy of pyrazole structures, especially known as potent CB2 receptor antagonists, we exploited an original and convergent synthesis of a new class of C4-benzyl pyrazolines and derivatives from readily available hydrazones and enones (two or three steps). Making use of a mixture of resin supported reagents strategy an efficient domino process allowed the easy construction of various dihydropyrazoles in 63-83% yields. The obtained family of pyrazolines featured significant hCB(2)/hCB(1) selectivity in favor of hCB(2) receptors while more than 1000-3000 nM affinity was only measured for hCB(1) receptors. This is closely related to pyrazole SR144528 inverse agonist/antagonist, although a partial agonist behavior in the [S-35]-GTP gamma S binding assay was mainly measured in our case pointing out a functional switch in action. Furthermore, this hCB(2) selectivity is unique within the pyrazoline CB ligands although the affinity ranging from 251 to 689 nM remains to be improved which give, however, an opportunity for further structure activity relationship. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.10.031

文献信息

• Biaryl Benzylamine Derivatives
  申请人：Angst Daniela

  公开号：US20100168079A1

  公开（公告）日：2010-07-01

  The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及双芳基-苄基胺化合物，其生产方法，作为药物的应用，以及包含它们的药物组合物。
• Dihydroimidazothiazole Derivatives
  申请人：Barba Oscar

  公开号：US20090221645A1

  公开（公告）日：2009-09-03

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT 1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.

  式(I)的化合物或其药学上可接受的盐，除了去甲肾上腺素再摄取抑制外，还表现出5-HT1A受体激动作用，可选地还具有5-HT再摄取抑制作用，适用于肥胖症的治疗。
• Rational Modification of a Candidate Cancer Drug for Use Against Chagas Disease
  作者：James M. Kraus、Christophe L. M. J. Verlinde、Mandana Karimi、Galina I. Lepesheva、Michael H. Gelb、Frederick S. Buckner

  DOI：10.1021/jm801313t

  日期：2009.3.26

  Chagas disease is one of the major neglected diseases of the world. Existing drug therapies are limited, ineffective, and highly toxic. We describe a novel strategy of drug discovery of adapting an existing clinical compound with excellent pharmaceutical properties to target a pathogenic organism. The protein farnesyltransferase (PFT) inhibitor tipifarnib, now in phase III anticancer clinical trials, was previously found to kill Trypanosoma cruzi by blocking sterol 14 alpha-demethylase (14DM). We rationally developed tipifarnib analogues that display reduced affinity for human PFT to reduce toxicity while increasing affinity for parasite 14DM. The lead compound has picomolar activity against cultured T. cruzi and is efficacious in a mouse model of acute Chagas disease.
• DIHYDROIMIDAZOTHIAZOLE DERIVATIVES
  申请人：Prosidion Limited

  公开号：EP1851232A2

  公开（公告）日：2007-11-07
• [EN] DIHYDROIMIDAZOTHIAZOLE DERIVATIVES<br/>[FR] DERIVES DE DIHYDRO-IMIDAZOTHIAZOLE
  申请人：PROSIDION LTD

  公开号：WO2006085118A2

  公开（公告）日：2006-08-17

  [EN] Compounds of formula (I): or pharmaceutically acceptable salts thereof, exhibit 5-HT_1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.
  [FR] L'invention concerne des composés de la formule (I), ou des sels pharmaceutiquement acceptables de ceux-ci, qui présentent un agonisme 5-HT_1A, outre l'inhibition de la recapture de la noradrénaline et éventuellement l'inhibition de la recapture de 5-HT, et qui sont utilisés dans le traitement de l'obésité.